Perioperative Analgesia
Effective perioperative pain management in GU reconstructive surgery is built on a multimodal, opioid-sparing philosophy — combining pharmacological agents with different mechanisms and regional techniques to achieve analgesia with minimal opioid burden. The goal is not opioid-free anesthesia, but a rational reduction in opioid dose that limits side effects (ileus, sedation, respiratory depression, nausea, urinary retention) while maintaining adequate pain control. This approach is central to ERAS implementation and is associated with reduced complications, faster return of bowel function, and shorter hospital stay.[1][3]
Key principle: A multimodal analgesic approach improves postoperative pain relief and reduces opioid use but is not universally implemented — deliberate pathway design is required.[3]
Preoperative Interventions
Risk Screening and Optimization
Before elective surgery, identify patients at elevated risk for adverse pain outcomes:
| Risk Profile | Clinical Features |
|---|---|
| High pain responders | History of chronic pain, catastrophizing, anxiety, depression |
| Persistent postoperative pain risk | Prior surgery with poor pain recovery, central sensitization |
| Persistent postoperative opioid use | Current opioid therapy, history of substance use disorder |
| Opioid misuse risk | OUD history, high-dose preoperative opioids, concurrent benzodiazepines |
| Opioid adverse event risk | Obesity with OSA, elderly, renal/hepatic impairment, pulmonary disease |
High-risk patients warrant multidisciplinary preoperative optimization — chronic pain service referral, psychiatric evaluation, opioid tapering when safe, and individualized analgesic planning.
Patient and Caregiver Education
Preoperative pain education improves postoperative outcomes and reduces opioid consumption. Topics to cover:
- Realistic expectations for postoperative pain (severity and trajectory)
- Non-pharmacological coping strategies (positioning, ice, relaxation)
- How and when to use rescue medications
- Recognition of side effects requiring medical attention
- Goals for opioid tapering and discontinuation
Preoperative Pharmacological Priming
Acetaminophen (oral, 1000 mg) and COX-2-specific inhibitors or NSAIDs (e.g., celecoxib 200–400 mg PO) given 1–2 hours preoperatively reduce intraoperative opioid requirements and postoperative pain scores. Contraindicated in severe hepatic failure (acetaminophen), renal impairment, active peptic ulcer, or cardiovascular contraindications (NSAIDs/COX-2).[1][3]
Gabapentinoids (gabapentin or pregabalin): If the patient is already receiving a gabapentinoid, continue perioperatively. De novo initiation for perioperative analgesia is not routinely recommended given risk of sedation and respiratory depression, particularly in the elderly, obese, or those with sleep apnea. Use only with careful patient selection and monitoring.[3]
Regional Analgesia Planning
Regional technique selection should be procedure-specific and patient-specific, planned before the day of surgery:
| Setting | Recommended Technique |
|---|---|
| Open thoracic or upper abdominal surgery (high-risk) | Epidural analgesia or paravertebral blocks; consider alternatives if possible |
| Major lower limb surgery under spinal anesthesia (high-risk) | Intrathecal morphine; consider alternatives if possible |
| Torso surgery (thoracic or abdominal wall) | Interfascial plane blocks (TAP, QL, ESP) |
| Major upper or lower extremity surgery | Peripheral nerve blocks |
| Perineal GU surgery | Pudendal nerve block, penile nerve block |
| Inguinal/scrotal procedures | Ilioinguinal/iliohypogastric block |
Intraoperative Interventions
Opioid-Sparing Anesthesia
The intraoperative goal is opioid-sparing, not opioid-free anesthesia. Judicious use of short-acting intraoperative opioids (fentanyl, remifentanil) is appropriate; the target is minimizing total opioid dose through concurrent use of non-opioid analgesics.
If not administered preoperatively: Acetaminophen (IV 1000 mg) and NSAIDs or COX-2 inhibitors (e.g., ketorolac 15–30 mg IV, or IV ibuprofen) should be given intraoperatively unless contraindicated.[3]
Analgesic Adjuncts
| Agent | Indication | Dose / Notes |
|---|---|---|
| Dexamethasone | All surgical patients (also antiemetic) | 8–10 mg IV once; analgesic and PONV prophylaxis |
| Ketamine | Opioid-tolerant patients; major surgery with significant expected postoperative pain | Low-dose IV infusion intraoperatively; no role for single bolus dose |
| Lidocaine IV | Open abdominal surgery when acetaminophen/NSAIDs and regional techniques are not being used | Continuous IV infusion intraoperatively; reduces opioid consumption and ileus |
| Dexmedetomidine IV | — | No established analgesic role in this context |
| Magnesium IV | — | No established analgesic role in this context |
Dexamethasone 8–10 mg IV is the most broadly applicable intraoperative analgesic adjunct — it reduces postoperative pain scores, opioid consumption, and PONV simultaneously with a single dose.[1][3]
Ketamine infusion is reserved for opioid-tolerant patients (chronic opioid users, patients on methadone/buprenorphine) undergoing major procedures with anticipated severe postoperative pain. A single bolus has no benefit; only infusion provides meaningful analgesia.[3]
Surgical Site Infiltration
Local anesthetic wound infiltration should be performed whenever anatomically possible at the conclusion of the procedure. Bupivacaine 0.25–0.5% or ropivacaine 0.2–0.5% infiltrated into the surgical wound layers provides immediate postoperative analgesia and reduces early opioid requirements. Liposomal bupivacaine (Exparel) extends duration to 72 hours for high-yield sites (perineal wounds, spermatic cord, port sites).[1]
Postoperative Interventions
Scheduled Non-Opioid Foundation
Round-the-clock scheduled dosing of non-opioids is superior to PRN dosing for postoperative analgesia:
| Agent | Dose | Frequency | Notes |
|---|---|---|---|
| Acetaminophen | 1000 mg PO/IV | Q6h (max 4 g/day) | Reduce to 2 g/day in hepatic impairment; 650 mg Q6h in elderly |
| Ibuprofen | 400–600 mg PO | Q6–8h with food | Avoid in renal impairment, GI risk, cardiovascular disease |
| Ketorolac | 15–30 mg IV/IM | Q6h, max 5 days | Renal function monitoring; do not exceed 5-day course |
| Celecoxib | 200 mg PO | Q12–24h | COX-2 selectivity reduces GI risk; avoid with cardiovascular contraindications |
| Meloxicam | 15 mg PO | Daily | Convenient once-daily dosing; renal/cardiovascular monitoring |
Graham et al. (2025, n=23,238) found that NSAIDs plus dexamethasone or regional anesthesia produced the greatest reduction in postoperative opioid consumption — notably, combinations including dexamethasone and NSAIDs outperformed acetaminophen-containing regimens for opioid reduction.[4]
Gabapentinoids (Continuation Only)
Continue gabapentin or pregabalin in patients already receiving these agents preoperatively. Do not initiate de novo postoperatively for routine pain management — risk of sedation and respiratory depression outweighs benefit, particularly in elderly, obese, and OSA patients.[3]
Opioid Rescue
When non-opioid multimodal analgesia is insufficient, use immediate-release opioids as rescue medication, preferably oxycodone IR (5–10 mg PO Q4–6h PRN). Key principles:
- Prescribe the minimum effective dose for the shortest necessary duration
- Reassess opioid need daily — taper and discontinue as pain resolves
- Avoid long-acting opioids for acute postoperative pain
- Tramadol has unpredictable pharmacogenomics and is not preferred
- IV PCA is appropriate for major open surgery with anticipated severe pain
Non-Pharmacological Interventions
| Modality | Application |
|---|---|
| Ice / cryotherapy | Perineal and scrotal swelling; reduces inflammation and pain |
| Elevation and compression | Extremity and genital edema post-surgery |
| Transcutaneous electrical nerve stimulation (TENS) | Adjunct for incisional pain |
| Early mobilization | Reduces pain sensitization and deconditioning |
| Psychological support / relaxation | Pain catastrophizing reduction; breathing techniques |
Regional Analgesia as Rescue
When postoperative pain is inadequately controlled despite the above, regional techniques can be applied as rescue — including peripheral nerve blocks placed in the recovery room or on the ward by the acute pain service.
GU-Specific Regional Nerve Blocks
Pudendal Nerve Block
Anatomy: The pudendal nerve (S2–S4) is the primary somatic nerve of the perineum, providing sensory innervation to the skin of the scrotum/labia, perineum, and penis/clitoris, and motor supply to the external urethral sphincter and external anal sphincter. It exits the pelvis via the greater sciatic foramen, wraps around the ischial spine, and re-enters via the lesser sciatic foramen to travel through Alcock's canal on the lateral wall of the ischiorectal fossa.
GU relevance: Perineal urethroplasty, AUS placement (perineal approach), penile prosthesis implantation (penoscrotal approach), perineal BNC/VUAS reconstruction, combined abdominoperineal approaches, vaginal/perineal prolapse repair, perineorrhaphy.
Techniques:
Transvaginal approach: Index finger palpates the ischial spine transvaginally; needle directed posterior and medial to the spine. Used in gynecological cases.
Transperineal / ultrasound-guided approach: Ultrasound identifies the internal pudendal artery at the level of the ischial spine within Alcock's canal; needle tip positioned in the pudendal canal. Preferred in male patients and for reconstructive procedures.
Agent and dose:
- 0.25–0.5% bupivacaine or 0.5% ropivacaine, 10–20 mL per side
- Bilateral block required for most perineal procedures
- No epinephrine — risk of perineal skin ischemia
- Liposomal bupivacaine (133 mg per side) extends duration to 48–72 hours
- Onset: 10–20 min; plain bupivacaine duration: 6–12 hours
Caution: High volumes at the ischial spine risk sciatic nerve spread; aspirate before injection; ultrasound guidance strongly preferred.
Dorsal Penile Nerve Block (DPNB)
Anatomy: The dorsal penile nerve is the terminal sensory branch of the pudendal nerve. It travels beneath Buck's fascia bilaterally along the dorsolateral surface of the penile shaft from the symphysis pubis to the glans, providing sensation to the dorsal penile skin and glans.
GU relevance: Penile prosthesis implantation (all approaches), circumcision, meatotomy, fossa navicularis urethroplasty, distal urethroplasty, penile skin procedures, DVIU.
Technique:
- Position needle at the base of the penis at the pubic symphysis
- Infiltrate at 10 o'clock and 2 o'clock positions (bilaterally, just below Buck's fascia)
- Needle advances until loss of resistance through Buck's fascia; inject after aspiration
- Alternatively: ring block — subcutaneous circumferential infiltration at the penile base (catches ventral branches not reached by DPNB alone)
Agent and dose:
- 0.25–0.5% bupivacaine, 5–10 mL per side (bilateral)
- Absolutely no epinephrine — the penile vasculature is an end-artery system; vasospasm causes ischemia and necrosis
- Duration: 6–12 hours (bupivacaine); liposomal bupivacaine can extend to 48–72h
Combined approach: DPNB + ring block at the penile base provides complete penile analgesia for implant cases; the ventral aspect (pump pocket area) is additionally covered by penoscrotal local infiltration.
Transversus Abdominis Plane (TAP) Block
Anatomy: The TAP block targets the T6–L1 intercostal, subcostal, ilioinguinal, and iliohypogastric nerves within the fascial plane between the internal oblique and transversus abdominis muscles.
GU relevance: Open and robotic cystectomy, sacrocolpopexy, Boari flap and psoas hitch, ileal ureter, Indiana pouch, radical prostatectomy, any procedure involving a midline or flank abdominal incision.
Limitations: Somatic analgesia only (abdominal wall) — no visceral coverage. Must be combined with other analgesics for intra-abdominal pain.
Technique: Ultrasound-guided; needle tip placed in the TAP plane with hydrodissection confirming correct layer. Laparoscopic TAP can be performed by the surgeon under direct vision at the end of a robotic/laparoscopic procedure.
Agent: 0.25% bupivacaine or 0.5% ropivacaine, 20–30 mL per side; bilateral blocks for midline incisions.
Ilioinguinal / Iliohypogastric Nerve Block
Anatomy: Both nerves arise from L1 (with T12 contribution) and travel between the internal oblique and transversus abdominis muscles, emerging near the anterior superior iliac spine (ASIS).
GU relevance: Penile prosthesis infrapubic approach, hydrocele repair, scrotal and inguinal procedures, Pfannenstiel incision.
Technique: Ultrasound-guided; needle targets the fascial plane medial and inferior to the ASIS. Both nerves are often blocked with a single injection at the correct sonographic plane.
Agent: 0.25% bupivacaine, 10–15 mL per side.
Quadratus Lumborum (QL) Block
Anatomy: Posterior interfascial plane block targeting the thoracolumbar fascia adjacent to the QL muscle. Unlike the TAP block, the QL block provides both somatic (abdominal wall T7–L1) and visceral analgesia via spread to the thoracic paravertebral space.
GU relevance: Major abdominal reconstruction, retroperitoneal surgery (renal autotransplantation, ileal ureter), upper tract reconstruction with flank/retroperitoneal exposure.
Types: QL1 (lateral), QL2 (posterior), QL3 / transmuscular QL (anterior) — deeper blocks provide more reliable visceral coverage.
Agent: 0.2–0.375% ropivacaine, 20–30 mL per side; bilateral for midline procedures.
Intrathecal (Spinal) Morphine
Intrathecal morphine added to a spinal anesthetic provides prolonged postoperative analgesia (12–24 hours) through central opioid receptors in the dorsal horn without the systemic burden of parenteral opioids.
GU relevance: Major perineal procedures performed under spinal anesthesia — perineal urethroplasty, combined abdominoperineal VUAS repair, AUS implantation.
Dose: 100–200 mcg intrathecally; higher doses increase analgesia but also increase side effects.
Critical safety consideration: Delayed respiratory depression (6–12 hours post-injection) requires monitored nursing unit or continuous pulse oximetry for 24 hours. Reserve for major procedures where benefit outweighs monitoring burden; consider alternative regional technique where possible.[3]
Side effects: Pruritus (very common), PONV, urinary retention, and delayed respiratory depression.
Emerging Agents
Suzetrigine (Journavx™)
Suzetrigine is the first FDA-approved non-opioid analgesic in over 25 years, receiving approval in January 2025 for moderate-to-severe acute pain. It is a selective Nav1.8 sodium channel blocker targeting peripheral nociceptors, with no CNS opioid activity, no abuse potential, and no respiratory depression risk.
Current evidence derives from Phase 2 trials in bunionectomy and abdominoplasty. Karri et al. (2025) note that "only the high dose showed superiority over placebo" with limited generalizability to major GU reconstructive surgery, and caution against overinterpretation of accelerated FDA review trial data.[2] Postmarket surveillance data in major surgery populations are awaited before routine incorporation into GU ERAS pathways.
Summary: Recommended Perioperative Analgesic Pathway
| Phase | Intervention | Notes |
|---|---|---|
| Preop | Acetaminophen 1000 mg PO + celecoxib 200–400 mg PO | 1–2h before incision; omit celecoxib if renal impairment, active peptic ulcer, or CV contraindication |
| Preop | Regional block planning | Procedure/patient-specific |
| Intraop | Dexamethasone 8–10 mg IV | Universal adjunct; also PONV prophylaxis |
| Intraop | Regional block execution | TAP, pudendal, penile, QL per case |
| Intraop | Wound infiltration | Bupivacaine or liposomal bupivacaine |
| Intraop | Ketamine infusion | Opioid-tolerant / major surgery only |
| Intraop | Lidocaine IV infusion | Open abdominal without regional or NSAIDs only |
| Postop | Acetaminophen 1000 mg Q6h + NSAID Q6–8h scheduled | Round-the-clock, not PRN; omit NSAID if renal impairment, GI risk, hepatic impairment, or CV contraindication |
| Postop | Oxycodone IR 5–10 mg Q4–6h PRN | Rescue only; taper and stop ASAP |
| Postop | Ice, elevation, early mobilization | Non-pharmacological adjuncts |
References
- Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review. JAMA Surg. 2017;152(7):691–697. PMID 28403389
- Karri J, D'Souza RS, Cohen SP. Between promise and peril: role of suzetrigine as a non-opioid analgesic. BMJ Med. 2025;4(1):e001431. PMID 40151204
- Joshi GP. Rational multimodal analgesia for perioperative pain management. Curr Pain Headache Rep. 2023;27(8):227–237. PMID 37405552
- Graham LA, Illarmo S, Wren SM, Mudumbai SC, Odden MC. Optimal multimodal analgesia combinations to reduce pain and opioid use following non-cardiac surgery: an instrumental variable analysis. Reg Anesth Pain Med. 2025. PMID 40659442